Long-Term Treatment of Postmenopausal Osteoporosis

Brown, Jacques P.

doi:10.3803/enm.2021.301

Cited by 88 publications

(50 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As indicated by related statistics, the number of global OP patients has exceeded 200 million, with approximately 9 million new cases and as many as 1.5 million osteoporotic fracture (OPF) patients in the United States each year [ 3 ]. OPFs, which account for about 80% of all fractures, are usually caused by injury or bone lesion-induced stress [ 4 , 5 ]. OPFs are shown to be often accompanied by postoperative bone pain (BP), which adversely affects patients' physical and mental health as well as activities of daily living [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

[Retracted] Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures

Wang

Sun

Shi

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. This research aims to investigate and analyze the impact of alendronate sodium (ALN) plus elcatonin (EC) in treating postoperative bone pain (BP) in patients with osteoporotic fractures (OPFs). Methods. One hundred and thirty-eight cases of OPFs admitted between July 2018 and July 2021 were selected, of which 68 cases receiving ALN were set as the control group and 70 cases receiving ALN plus EC were set as the research group. Intercomparisons were performed in terms of BP, curative effect, complication rate, and serum bone metabolism indexes such as bone Gla protein (BGP), parathyroid hormone (PTH), and bone alkaline phosphatase (BALP). Results. Better postoperative BP relief, higher overall response rate, and lower complication rate were identified in the research group versus the control group. On the other hand, the research group presented with increased BGP and BALP after treatment, higher than those in the control group, while the posttreament PTH decreased obviously and was lower versus the control group.Conclusions. For OPF patients, ALN plus EC contributes to significantly reduced postoperative BP, improved clinical efficacy, higher treatment safety, and better bone metabolism, which has high clinical application value.

show abstract

Section: Introductionmentioning

confidence: 99%

[Retracted] Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures

Wang

Sun

Shi

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Current anti-osteoporotic medications have limitations, including side effects and long-term ineffectiveness [ 4 , 5 , 7 , 9 ]. Efforts have therefore sought to identify novel drugs targeting osteoporosis.…”

Section: Discussionmentioning

confidence: 99%

“…As the worldwide population ages, so do the frequency and importance of osteoporosis and related fractures, which are associated with large socioeconomic burdens [3]. At present, anti-resorptive agents, such as bisphosphonates and denosumab, are the most widely used medications worldwide in the treatment of osteoporosis [4]. Due to a coupling phenomenon, however, these agents concomitantly suppress bone formation, limiting their efficacy and possibly leading to increases in adverse events [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates

Lee

Park

Lee

et al. 2022

Korean J Intern Med

View full text Add to dashboard Cite

Background/Aims: Lumican, a small leucine-rich proteoglycan, has shown osteoprotective effects by synchronously stimulating bone formation and suppressing bone resorption. To clarify the role of lumican in human bone metabolism, the association between lumican concentrations and osteoporosis-related phenotypes was evaluated using bone marrow (BM) samples directly reflecting local microenvironments.Methods: BM aspirates were obtained from 77 patients during hip surgery for either fragility hip fractures (HF) (n = 29) or osteoarthritis (n = 48) and centrifuged. Concentrations of lumican and biochemical bone markers in BM supernatants were measured using enzyme linked immunosorbent assays.Results: After considering confounders, lumican concentrations in BM supernatants were 16.9% lower in patients with HF than in controls, with each increase in the standard deviation of lumican concentration being associated with a 61% lower likelihood of HF. The odds ratios for HF decreased linearly with increasing lumican tertiles in BM, with the odds of having fragility HF markedly lower in participants in the highest than in the lowest lumican tertile. Higher lumican level correlated significantly with higher femur neck bone mineral density and higher bone-specific alkaline phosphatase levels, but not with tartrate-resistant acid phosphatase 5b concentrations, in BM supernatants.Conclusions: These data clinically validate previous <i>in vitro</i> and animal experiments showing the beneficial roles of lumican for bone homeostasis and suggest that lumican may contribute to a reduction in fracture risk in humans mainly through its stimulation of bone formation.

show abstract

“… 3 ) Based on the underlying mechanisms of osteoporosis, many effective drugs, such as anti-resorptives or bone-forming agents, have been developed and used in clinical practice to improve bone strength. 6 ) However, despite these efforts, decreases in the incidence of osteoporosis and resultant fractures have been stagnant, thereby forming the major cause of increased morbidity and mortality in older adults. Given the multifaceted pathogenesis of fragility fractures, a systemic approach to various risk factors besides deteriorated bone health is essential for fracture prevention.…”

Section: Introductionmentioning

confidence: 99%

Effects of Muscles on Bone Metabolism—with a Focus on Myokines

Kim¹

2022

Ann Geriatr Med Res

View full text Add to dashboard Cite

Skeletal muscles and bones, the largest tissues in the body of a non-obese person, comprise the musculoskeletal system, which allows mobility and protects internal organs. Although muscles and bones are intimately related throughout life, observations during development and aging and in human and animal disuse models have revealed the synchronization of tissue mass such that muscle phenotype changes precede alterations in bone mineral density and strength. This review discussed that mechanical forces, which have been the traditional research focus, are not the only mechanism by which muscle-derived signals may affect bone metabolism and emphasized the significance of skeletal muscles as an endocrine organ that secretes bone-regulatory factors. Consequently, both mechanical and biochemical aspects should be considered to fully understand muscle–bone crosstalk. This review also suggested that specific myokines could be ideal therapeutic targets for osteoporosis to both increase bone formation and reduce bone resorption; moreover, these myokines could also be potential circulating biomarkers to predict musculoskeletal health.

show abstract

Long-Term Treatment of Postmenopausal Osteoporosis

Cited by 88 publications

References 59 publications

[Retracted] Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures

[Retracted] Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures

Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates

Effects of Muscles on Bone Metabolism—with a Focus on Myokines

Contact Info

Product

Resources

About